Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parallel-group, randomized, double-blind phase IIa umbrella study of frexalimab, brivekimig (SAR442970) and rilzabrutinib in primary FSGS or MCD
CTR20250150Phase 2Active
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of frexalimab, brivekimig and rilzabrutinib in focal segmental glomerulosclerosis (FSGS) and nephrosis (6 arms), sponsored by Sanofi. Primary endpoint: Percent reduction in urine protein-to-creatinine ratio (UPCR) from baseline to week 12. Started May 2025; status: active.
02
Drugs
frexalimabbrivekimigrilzabrutinib
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosis
Beyond the preview
Go deeper on CTR20250150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250150.